16 research outputs found

    Spectral distribution of SPARC photoinjector electrons

    Get PDF
    SPARC is a photo-injector for production of high-brightness lowemittance electron beams to drive a FEL experiment in various configurations, including SASE-FEL radiation of 1–10nm (SPARCX project). Due to a high-brightness source, the SPARC facility can be used to study the physics of ultrashort beams, plasma-wave based acceleration, production of X-rays by means of Compton backscattering, channeling of electron beams and other experiments. The initial process of electron beam generation inside the RF gun determines the main parameters of the electron beam. Interaction of electrons with high-frequency laser beam leads to modulation of the electron beam. In this paper we present electron beam spectral distribution for SPARC photoinjector parameters. The estimate of electron beam energy loss for such electron distribution also is given

    ΠšΠ»ΠΈΠ½ΠΈΡ‡Π΅ΡΠΊΠ°Ρ Π·Π½Π°Ρ‡ΠΈΠΌΠΎΡΡ‚ΡŒ Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏΠ° ΠΈΠΌΠΌΡƒΠ½Π½Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²ΠΎΠΉ стромы Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹

    Get PDF
    Introduction. Prostate cancer is by far the most frequently diagnosed cancer among the male population and ranks fifth in the world in terms of mortality rates among malignant neoplasms. Today it is known that the tumor microenvironment plays an important role in the pathogenesis of the disease. Abundant data has accumulated indicating that cells of the inflammatory infiltrate of the tumor are involved in the onset, progression and response to treatment in cases of prostate cancer. However, their role in the context of disease progression has not yet been determined. In this work, we studied the phenotype of inflammatory infiltrate of prostate cancer and its association with the clinical and morphological characteristics of patients.The study objective is to determine the features of the inflammatory infiltrate of prostate cancer and its association with the clinical and morphological characteristics of patients with this disease.Materials and methods. The study included tumor samples obtained from 31 patients with prostate cancer. The expression of CD3, CD8, FoxP3, CD68, PU.1, CD204, CD163, IDO1, PD-L1 (programmed death-ligand 1) was assessed by immunohistochemistry. The relationship between markers and clinical and morphological characteristics was assessed using the nonparametric Mann–Whitney test and Fisher’s exact test. Spearman’s rank correlation coefficient was used to analyze the correlations between contents of cells of different phenotypes. Differences were considered statistically significant at p <0.05.Results. This study describes the features of the stroma of prostate cancer. We have shown that an increased content of CD204+ cells is associated with an older age of patients (p = 0.0026), and the number of CD163+ and CD8+ cells with no metastases to regional lymph nodes (p = 0.0067 and p = 0.0069, respectively). It has been shown that PU.1 can be used as a general marker of macrophages. We also found significant correlations between the level of PU.1 and PD-L1 in the stroma (r = 0.421; p = 0.018) and IDO1 in the stroma (r = 0.557; p = 0.001) and in tumor cells (r = 0.393; p = 0.029), CD68 with IDO1 in the stroma (r = 0.535; p = 0.002), CD163 with PD-L1 and IDO1 in the stroma (r = 0.399; p = 0.026 and r = 0.220; p = 0.026, respectively).Conclusion. In this work, the characteristics of the stroma of prostate cancer were investigated. Our data indicate that tumor associated macrophages are the main cells expressing PD-L1 and IDO1 in the tumor stroma in the case of prostate cancer. Increased expression of IDO1 in tumor tissue is associated with the immunosuppressive phenotype of the inflammatory infiltrate. The fact that the number of macrophages directly correlates with the number of T-lymphocytes in the prostate stroma, and the number of M2 macrophages with cytotoxic T-cells indicates the interaction of the mechanisms of innate and acquired immunity during the progression of prostate cancer.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. Π Π°ΠΊ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ Π½Π° сСгодняшний дСнь являСтся Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ часто диагностируСмым онкологичСским Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ срСди муТского насСлСния ΠΈ Π·Π°Π½ΠΈΠΌΠ°Π΅Ρ‚ 5-Π΅ мСсто Π² ΠΌΠΈΡ€Π΅ ΠΏΠΎ показатСлям смСртности срСди злокачСствСнных Π½ΠΎΠ²ΠΎΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. Π˜Π·Π²Π΅ΡΡ‚Π½ΠΎ, Ρ‡Ρ‚ΠΎ ΠΌΠΈΠΊΡ€ΠΎΠΎΠΊΡ€ΡƒΠΆΠ΅Π½ΠΈΠ΅ ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΠΈΠ³Ρ€Π°Π΅Ρ‚ Π±ΠΎΠ»ΡŒΡˆΡƒΡŽ Ρ€ΠΎΠ»ΡŒ Π² ΠΏΠ°Ρ‚ΠΎΠ³Π΅Π½Π΅Π·Π΅ заболСвания. НакоплСно ΠΌΠ½ΠΎΠ³ΠΎ Π΄Π°Π½Π½Ρ‹Ρ…, ΡΠ²ΠΈΠ΄Π΅Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΡƒΡŽΡ‰ΠΈΡ… ΠΎ Ρ‚ΠΎΠΌ, Ρ‡Ρ‚ΠΎ ΠΊΠ»Π΅Ρ‚ΠΊΠΈ Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΈΠ½Ρ„ΠΈΠ»ΡŒΡ‚Ρ€Π°Ρ‚Π° ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΡƒΡ‡Π°ΡΡ‚Π²ΡƒΡŽΡ‚ Π² Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΠΈ, прогрСссии ΠΈ ΠΎΡ‚Π²Π΅Ρ‚Π΅ Π½Π° Π»Π΅Ρ‡Π΅Π½ΠΈΠ΅ Π² случаях Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹. Однако ΠΈΡ… Ρ€ΠΎΠ»ΡŒ Π² контСкстС прогрСссии заболСвания Π΅Ρ‰Π΅ Π½Π΅ ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½Π°. Π² ΡΡ‚Π°Ρ‚ΡŒΠ΅ прСдставлСно исслСдованиС Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏΠ° Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΈΠ½Ρ„ΠΈΠ»ΡŒΡ‚Ρ€Π°Ρ‚Π° Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ ΠΈ Π΅Π³ΠΎ ассоциации с ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-морфологичСскими характСристиками ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ².ЦСль исслСдования – ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ особСнностСй Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΈΠ½Ρ„ΠΈΠ»ΡŒΡ‚Ρ€Π°Ρ‚Π° Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ ΠΈ Π΅Π³ΠΎ ассоциации с ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-морфологичСскими характСристиками ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π΄Π°Π½Π½Ρ‹ΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ исслСдованиС Π±Ρ‹Π»ΠΈ Π²ΠΊΠ»ΡŽΡ‡Π΅Π½Ρ‹ ΠΎΠ±Ρ€Π°Π·Ρ†Ρ‹ ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ, ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Π΅ ΠΎΡ‚ 31 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° с Ρ€Π°ΠΊΠΎΠΌ ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹. Π‘ ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ иммуногистохимичСского исслСдования ΠΏΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Π° экспрСссия CD3, CD8, FoxP3, CD68, PU.1, CD204, CD163, IDO1 ΠΈ PD-L1 (Π»ΠΈΠ³Π°Π½Π΄Π° Ρ€Π΅Ρ†Π΅ΠΏΡ‚ΠΎΡ€Π° ΠΏΡ€ΠΎΠ³Ρ€Π°ΠΌΠΌΠΈΡ€ΡƒΠ΅ΠΌΠΎΠΉ ΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½ΠΎΠΉ Π³ΠΈΠ±Π΅Π»ΠΈ 1). Для опрСдСлСния взаимосвязи ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ² ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-морфологичСских характСристик ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² использовались нСпарамСтричСский ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠΉ манна–Уитни ΠΈ Ρ‚ΠΎΡ‡Π½Ρ‹ΠΉ ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠΉ Ρ„ΠΈΡˆΠ΅Ρ€Π°. Для Π°Π½Π°Π»ΠΈΠ·Π° коррСляций ΠΌΠ΅ΠΆΠ΄Ρƒ содСрТаниСм ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏΠΎΠ² примСняли коэффициСнт Ρ€Π°Π½Π³ΠΎΠ²ΠΎΠΉ коррСляции спирмСна. Π²ΠΎ всСх Π°Π½Π°Π»ΠΈΠ·Π°Ρ… Π·Π½Π°Ρ‡Π΅Π½ΠΈΠ΅ p ≀0,05 ΡΡ‡ΠΈΡ‚Π°Π»ΠΎΡΡŒ статистичСски Π·Π½Π°Ρ‡ΠΈΠΌΡ‹ΠΌ.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π’ Ρ…ΠΎΠ΄Π΅ исслСдования ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½Ρ‹ особСнности стромы Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹. Π‘Ρ‹Π»ΠΎ продСмонстрировано, Ρ‡Ρ‚ΠΎ ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½Π½ΠΎΠ΅ содСрТаниС CD204+-ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ассоциировано с Π±ΠΎΠ»Π΅Π΅ ΡΡ‚Π°Ρ€ΡˆΠΈΠΌ возрастом ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² (Ρ€ = 0,0026), Π° количСство CD163+- ΠΈ CD8+-ΠΊΠ»Π΅Ρ‚ΠΎΠΊ – с отсутствиСм мСтастазов Π² Ρ€Π΅Π³ΠΈΠΎΠ½Π°Ρ€Π½Ρ‹Π΅ лимфатичСскиС ΡƒΠ·Π»Ρ‹ (Ρ€ = 0,0067 ΠΈ Ρ€ = 0,0069 соотвСтствСнно). Показано, Ρ‡Ρ‚ΠΎ PU.1 ΠΌΠΎΠΆΠ΅Ρ‚ Π±Ρ‹Ρ‚ΡŒ использован ΠΊΠ°ΠΊ ΠΎΠ±Ρ‰ΠΈΠΉ ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ ΠΌΠ°ΠΊΡ€ΠΎΡ„Π°Π³ΠΎΠ². Π’Π°ΠΊΠΆΠ΅ ΠΌΡ‹ выявили достовСрныС коррСляции уровня PU.1 с PD-L1 Π² стромС (r = 0,421; Ρ€ = 0,018), IDO1 Π² стромС (r = 0,557; p = 0,001) ΠΈ ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… (r = 0,393; Ρ€ = 0,029), Π° Ρ‚Π°ΠΊΠΆΠ΅ CD68 c IDO1 (r = 0,535; p = 0,002) ΠΈ сD163 c PDL1 ΠΈ IDO1 Π² стромС (r = 0,399; p = 0,026 ΠΈ r = 0,220; p = 0,026 соотвСтствСнно).Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π‘Ρ‹Π»ΠΈ исслСдованы характСристики стромы Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹. ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Π΅ Π΄Π°Π½Π½Ρ‹Π΅ ΡƒΠΊΠ°Π·Ρ‹Π²Π°ΡŽΡ‚ Π½Π° Ρ‚ΠΎ, Ρ‡Ρ‚ΠΎ основными ΠΊΠ»Π΅Ρ‚ΠΊΠ°ΠΌΠΈ, ΡΠΊΡΠΏΡ€Π΅ΡΡΠΈΡ€ΡƒΡŽΡ‰ΠΈΠΌΠΈ PD-L1 ΠΈ IDO1 Π² стромС ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ, Π² случаС Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹ ΡΠ²Π»ΡΡŽΡ‚ΡΡ ΠΌΠ°ΠΊΡ€ΠΎΡ„Π°Π³ΠΈ, ΠΈΠ½Ρ„ΠΈΠ»ΡŒΡ‚Ρ€ΠΈΡ€ΡƒΡŽΡ‰ΠΈΠ΅ ΠΎΠΏΡƒΡ…ΠΎΠ»ΡŒ. ΠŸΠΎΠ²Ρ‹ΡˆΠ΅Π½Π½Π°Ρ экспрСссия IDO1 Π² ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²ΠΎΠΉ Ρ‚ΠΊΠ°Π½ΠΈ ассоциирована с иммуносупрСссорным Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏΠΎΠΌ Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΈΠ½Ρ„ΠΈΠ»ΡŒΡ‚Ρ€Π°Ρ‚Π°. Ρ‚ΠΎΡ‚ Ρ„Π°ΠΊΡ‚, Ρ‡Ρ‚ΠΎ количСство ΠΌΠ°ΠΊΡ€ΠΎΡ„Π°Π³ΠΎΠ² прямо ΠΊΠΎΡ€Ρ€Π΅Π»ΠΈΡ€ΡƒΠ΅Ρ‚ с количСством Ρ‚-Π»ΠΈΠΌΡ„ΠΎΡ†ΠΈΡ‚ΠΎΠ² Π² стромС Ρ€Π°ΠΊΠ° ΠΏΡ€Π΅Π΄ΡΡ‚Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ‹, Π° ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ содСрТания ΠΌΠ°ΠΊΡ€ΠΎΡ„Π°Π³ΠΎΠ² 2-Π³ΠΎ Ρ‚ΠΈΠΏΠ° – с цитотоксичСскими Ρ‚-ΠΊΠ»Π΅Ρ‚ΠΊΠ°ΠΌΠΈ, ΡΠ²ΠΈΠ΄Π΅Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΡƒΠ΅Ρ‚ ΠΎ взаимодСйствии ΠΌΠ΅Ρ…Π°Π½ΠΈΠ·ΠΌΠΎΠ² Π²Ρ€ΠΎΠΆΠ΄Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈ ΠΏΡ€ΠΈΠΎΠ±Ρ€Π΅Ρ‚Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡƒΠ½ΠΈΡ‚Π΅Ρ‚Π° Π² процСссС прогрСссии ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ

    Π˜ΠΌΠΌΡƒΠ½ΠΎΡΡƒΠΏΡ€Π΅ΡΡΠΎΡ€Π½Ρ‹Π΅ особСнности Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏΠ° стромы ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡ‡ΠΊΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… гистологичСских Ρ‚ΠΈΠΏΠΎΠ²

    Get PDF
    Background. Renal cell carcinoma is a heterogeneous group of tumors characterized by high vascularization and immunogenicity. Immunotherapy has made a breakthrough in the treatment of this pathology, however, the lack of development of criteria for its use does not allow to achieve even greater success. It is known that the tumor stroma plays an important role in the success of immunotherapy. Among the various histological types of kidney tumors, the stroma of the clear cell renal cell carcinoma has been studied in sufficient detail. However, the remaining histological types are practically not studied.Objective: description of the immunosuppressive phenotype of the stroma of kidney tumors of various histological types.Materials and methods. The study included tumor samples obtainedfrom 44patients with renal cell carcinoma of various histological types (16 samples of chromophobe cancer, 15 samples of clear cell and 13 samples of papillary renal cell carcinoma). The method of immunohis-tochemistry evaluated the expression of tumor stromal markers, namely CD68, CD206, PU.1, CD3, IDO1 and PD-L1 in the studied samples.Results. Analysis of the total number of macrophages associated with the tumor showed that the smallest number is observed in samples of chromophobe renal cancer, while in the samples of clear cell cancer their number is greatest. A similar situation is observed for T-cells: the largest number of CD3+ cells is observed in clear cell tumors. In chromophobe and papillary tumors, their number is reduced. Papillary tumors are also characterized by an almost complete absence of expression of PD-L1 and IDO1 compared to other histological types of kidney tumors. We also showed that for PU.1 there is a strong positive correlation between its quantity and localization, as in CD68. Thus, PU.1 can be used as a general marker for describing stromal macrophages in kidney tumors.Conclusion. The study showed that kidney tumors of various histological types strongly and significantly differ in the composition of their microenvironment. These data, of course, must be considered when choosing immune therapy in the treatment of this pathology.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠŸΠΎΡ‡Π΅Ρ‡Π½ΠΎ-клСточная ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠ° прСдставляСт собой Π³Π΅Ρ‚Π΅Ρ€ΠΎΠ³Π΅Π½Π½ΡƒΡŽ Π³Ρ€ΡƒΠΏΠΏΡƒ ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²Ρ‹Ρ… Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΡƒΡŽΡ‰ΡƒΡŽΡΡ высокой Π²Π°ΡΠΊΡƒΠ»ΡΡ€ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΡΡ‚ΡŒΡŽ ΠΈ ΠΈΠΌΠΌΡƒΠ½ΠΎΠ³Π΅Π½Π½ΠΎΡΡ‚ΡŒΡŽ. Π˜ΠΌΠΌΡƒΠ½ΠΎΡ‚Π΅Ρ€Π°ΠΏΠΈΡ ΡΠΎΠ²Π΅Ρ€ΡˆΠΈΠ»Π° ΠΏΡ€ΠΎΡ€Ρ‹Π² Π² Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΠΎΠ΄Π½Π°ΠΊΠΎ Π½Π΅Π΄ΠΎΡΡ‚Π°Ρ‚ΠΎΡ‡Π½ΠΎΡΡ‚ΡŒ Π²Ρ‹Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² Π΅Π΅ примСнСния Π½Π΅ позволяСт Π΄ΠΎΠ±ΠΈΡ‚ΡŒΡΡ Π΅Ρ‰Π΅ Π±ΠΎΠ»ΡŒΡˆΠΈΡ… успСхов. Π˜Π·Π²Π΅ΡΡ‚Π½ΠΎ, Ρ‡Ρ‚ΠΎ Π² успСхС ΠΈΠΌΠΌΡƒΠ½ΠΎΡ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π½Π΅ΠΌΠ°Π»ΠΎΠ²Π°ΠΆΠ½ΡƒΡŽ Ρ€ΠΎΠ»ΡŒ ΠΈΠ³Ρ€Π°Π΅Ρ‚ опухолСвая строма. Π‘Ρ€Π΅Π΄ΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… гистологичСских Ρ‚ΠΈΠΏΠΎΠ² ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡ‡ΠΊΠΈ строма свСтлоклСточного Π²Π°Ρ€ΠΈΠ°Π½Ρ‚Π° ΠΏΠΎΡ‡Π΅Ρ‡Π½ΠΎ-ΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½ΠΎΠΉ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹ ΠΈΠ·ΡƒΡ‡Π΅Π½Π° достаточно ΠΏΠΎΠ΄Ρ€ΠΎΠ±Π½ΠΎ. Однако ΠΎΡΡ‚Π°Π»ΡŒΠ½Ρ‹Π΅ гистологичСскиС Ρ‚ΠΈΠΏΡ‹ практичСски Π½Π΅ ΠΈΠ·ΡƒΡ‡Π΅Π½Ρ‹.ЦСль исслСдования β€” описаниС иммуносупрСссорного Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏΠ° стромы ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡ‡ΠΊΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… гистологичСских Ρ‚ΠΈΠΏΠΎΠ². ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ исслСдованиС Π±Ρ‹Π»ΠΈ Π²ΠΊΠ»ΡŽΡ‡Π΅Π½Ρ‹ ΠΎΠ±Ρ€Π°Π·Ρ†Ρ‹ ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ, ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Π΅ ΠΎΡ‚ 44 Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… ΠΏΠΎΡ‡Π΅Ρ‡Π½ΠΎ-ΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½Ρ‹ΠΌ Ρ€Π°ΠΊΠΎΠΌ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… гистологичСских Ρ‚ΠΈΠΏΠΎΠ² (16 ΠΎΠ±Ρ€Π°Π·Ρ†ΠΎΠ² Ρ…Ρ€ΠΎΠΌΠΎΡ„ΠΎΠ±Π½ΠΎΠ³ΠΎ, 15 ΠΎΠ±Ρ€Π°Π·Ρ†ΠΎΠ² свСтлоклСточного ΠΈ 13 ΠΎΠ±Ρ€Π°Π·Ρ†ΠΎΠ² папиллярного Ρ€Π°ΠΊΠ° ΠΏΠΎΡ‡ΠΊΠΈ). Π’ исслСдуСмых ΠΎΠ±Ρ€Π°Π·Ρ†Π°Ρ… иммуногистохимичСски ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡ†Π΅Π½ΠΊΠ° экспрСссии ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ² ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²ΠΎΠΉ стромы, Π° ΠΈΠΌΠ΅Π½Π½ΠΎ CD68, CD206, PU.1, CD3, IDO1 ΠΈ PD-L1.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Анализ ΠΎΠ±Ρ‰Π΅Π³ΠΎ числа ΠΌΠ°ΠΊΡ€ΠΎΡ„Π°Π³ΠΎΠ², ассоциированных с ΠΎΠΏΡƒΡ…ΠΎΠ»ΡŒΡŽ, ΠΏΠΎΠΊΠ°Π·Π°Π», Ρ‡Ρ‚ΠΎ наимСньшСС ΠΈΡ… количСство Π½Π°Π±Π»ΡŽΠ΄Π°Π΅Ρ‚ΡΡ Π² ΠΎΠ±Ρ€Π°Π·Ρ†Π°Ρ… Ρ…Ρ€ΠΎΠΌΠΎΡ„ΠΎΠ±Π½ΠΎΠ³ΠΎ Ρ€Π°ΠΊΠ° ΠΏΠΎΡ‡ΠΊΠΈ, Π² Ρ‚ΠΎ врСмя ΠΊΠ°ΠΊ Π² ΠΎΠ±Ρ€Π°Π·Ρ†Π°Ρ… свСтлоклСточного Ρ€Π°ΠΊΠ° ΠΈΡ… количСство наибольшСС. Для Π’-ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½Π° похоТая ситуация: наибольшСС число CD3+-ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π½Π°Π±Π»ΡŽΠ΄Π°Π΅Ρ‚ΡΡ Π² свСтлоклСточных опухолях. Π’ Ρ…Ρ€ΠΎΠΌΠΎΡ„ΠΎΠ±Π½Ρ‹Ρ… ΠΈ папиллярных опухолях ΠΈΡ… количСство сниТСно. Π’Π°ΠΊΠΆΠ΅ папиллярныС ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΡƒΡŽΡ‚ΡΡ практичСски ΠΏΠΎΠ»Π½Ρ‹ΠΌ отсутствиСм экспрСссии PD-L1 ΠΈ IDO1 ΠΏΠΎ ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ с Π΄Ρ€ΡƒΠ³ΠΈΠΌΠΈ гистологичСскими Ρ‚ΠΈΠΏΠ°ΠΌΠΈ ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡ‡ΠΊΠΈ. Π’Π°ΠΊΠΆΠ΅ ΠΌΡ‹ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, Ρ‡Ρ‚ΠΎ для PU.1 Π½Π°Π±Π»ΡŽΠ΄Π°Π΅Ρ‚ΡΡ сильная ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½Π°Ρ коррСляция Π΅Π³ΠΎ количСства с Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°Ρ†ΠΈΠ΅ΠΉ, ΠΊΠ°ΠΊ ΠΈ для CD68. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±Ρ€Π°Π·ΠΎΠΌ, PU.1 ΠΌΠΎΠΆΠ½ΠΎ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Ρ‚ΡŒ Π² качСствС ΠΎΠ±Ρ‰Π΅Π³ΠΎ ΠΌΠ°Ρ€ΠΊΠ΅Ρ€Π° для описания ΡΡ‚Ρ€ΠΎΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΌΠ°ΠΊΡ€ΠΎΡ„Π°Π³ΠΎΠ² Π² опухолях ΠΏΠΎΡ‡ΠΊΠΈ.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ исслСдования ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, Ρ‡Ρ‚ΠΎ ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΠΏΠΎΡ‡ΠΊΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… гистологичСских Ρ‚ΠΈΠΏΠΎΠ² сильно ΠΈ Π·Π½Π°Ρ‡ΠΈΠΌΠΎ ΠΎΡ‚Π»ΠΈΡ‡Π°ΡŽΡ‚ΡΡ ΠΏΠΎ составу своСго микроокруТСния. Π­Ρ‚ΠΎ, нСсомнСнно, Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎ ΡƒΡ‡ΠΈΡ‚Ρ‹Π²Π°Ρ‚ΡŒ ΠΏΡ€ΠΈ Π²Ρ‹Π±ΠΎΡ€Π΅ ΠΈΠΌΠΌΡƒΠ½Π½ΠΎΠΉ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π² Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΠΈ

    Π‘Π΅Π»ΠΊΠΈ sPD-1/sPD-L1 ΠΏΡ€ΠΈ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½ΠΎΠΌ Ρ€Π°ΠΊΠ΅ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ плоскоклСточном Ρ€Π°ΠΊΠ΅ ΠΏΠΈΡ‰Π΅Π²ΠΎΠ΄Π°

    Get PDF
    Background. Implementation of immunotherapy in clinical oncological practice has significantly improved the results of cancer treatment. It resulted in the need for seeking new markers to assess the effectiveness of therapy and the disease prognosis.Aim. To analyze the content of soluble forms of PD-1 and PD-L1 immune checkpoint proteins in the blood serum of patients with non-small cell lung cancer and esophageal squamous cell carcinoma and their association with clinical and morphological characteristics of the disease and the disease prognosis.Materials and methods. The study included tumor samples obtained from 43 patients with non-small cell lung cancer and 21 patients with esophageal squamous cell carcinoma. The concentration of sPD-L1 and sPD-1 in the blood serum was determined using enzyme-linked immunosorbent assay (ELISA). The Mann – Whitney test was used to determine statistically significant differences in independent groups. A correlation analysis was performed using the Spearman’s rank correlation coefficient. Overall survival was analyzed by constructing survival curves using the Kaplan – Meier method and a Cox proportional hazards model. The differences were considered statistically significant at p < 0.05.Results. The study showed that sPD-1 and sPD-L1 were found in the blood serum of both cancer patients and healthy donors, and their concentrations did not differ significantly. It was shown that the high concentration of sPD-L1 in the blood serum of patients with non-small cell lung cancer was significantly associated with the late stage of the disease and was an independent unfavorable prognostic factor. It should be noted that for patients with esophageal cancer, an unfavorable prognostic marker was the high concentration of the soluble form of PD-1 protein, and not PD-L1 ligand, as in case of lung cancer.Conclusion. The content of sPD-1 and sPD-L1 in the blood serum can have different prognostic significance for various types of cancer, and further studies are required to confirm their clinical usability.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. АктивноС Π²Π½Π΅Π΄Ρ€Π΅Π½ΠΈΠ΅ ΠΈΠΌΠΌΡƒΠ½ΠΎΡ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π² ΠΊΠ»ΠΈΠ½ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ ΠΏΡ€Π°ΠΊΡ‚ΠΈΠΊΡƒ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ ΡƒΠ»ΡƒΡ‡ΡˆΠΈΡ‚ΡŒ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ лСкарствСнного лСчСния ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ. Π­Ρ‚ΠΎ ΠΏΡ€ΠΈΠ²Π΅Π»ΠΎ ΠΊ нСобходимости поиска Π½ΠΎΠ²Ρ‹Ρ… ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ², с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… ΠΌΠΎΠΆΠ½ΠΎ ΠΎΡ†Π΅Π½ΠΈΡ‚ΡŒ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ ΠΈ ΠΏΡ€ΠΎΠ³Π½ΠΎΠ· заболСвания.ЦСль исслСдования – Π°Π½Π°Π»ΠΈΠ· содСрТания растворимых Ρ„ΠΎΡ€ΠΌ Π±Π΅Π»ΠΊΠΎΠ² ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Ρ‚ΠΎΡ‡Π΅ΠΊ ΠΈΠΌΠΌΡƒΠ½ΠΈΡ‚Π΅Ρ‚Π° sPD-1 ΠΈ PD-L1 Π² сывороткС ΠΊΡ€ΠΎΠ²ΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½Ρ‹ΠΌ Ρ€Π°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ плоскоклСточным Ρ€Π°ΠΊΠΎΠΌ ΠΏΠΈΡ‰Π΅Π²ΠΎΠ΄Π°, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΈΡ… ассоциации с ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-морфологичСскими характСристиками заболСвания ΠΈ ΠΏΡ€ΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ исслСдованиС Π²ΠΊΠ»ΡŽΡ‡Π΅Π½Ρ‹ ΠΎΠ±Ρ€Π°Π·Ρ†Ρ‹ ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ ΠΎΡ‚ 43 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½Ρ‹ΠΌ Ρ€Π°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ 21 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° с плоскоклСточным Ρ€Π°ΠΊΠΎΠΌ ΠΏΠΈΡ‰Π΅Π²ΠΎΠ΄Π°. ΠšΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΡŽ sPD-L1 ΠΈ sPD-1 опрСдСляли Π² сывороткС ΠΊΡ€ΠΎΠ²ΠΈ с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ΠΈΠΌΠΌΡƒΠ½ΠΎΡ„Π΅Ρ€ΠΌΠ΅Π½Ρ‚Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. Для опрСдСлСния статистичСски Π·Π½Π°Ρ‡ΠΈΠΌΡ‹Ρ… Ρ€Π°Π·Π»ΠΈΡ‡ΠΈΠΉ Π² нСзависимых Π³Ρ€ΡƒΠΏΠΏΠ°Ρ… использовали ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠΉ Манна – Π£ΠΈΡ‚Π½ΠΈ. ΠšΠΎΡ€Ρ€Π΅Π»ΡΡ†ΠΈΠΎΠ½Π½Ρ‹ΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ опрСдСлСния коэффициСнта Ρ€Π°Π½Π³ΠΎΠ²ΠΎΠΉ коррСляции Π‘ΠΏΠΈΡ€ΠΌΠ΅Π½Π°. Анализ ΠΎΠ±Ρ‰Π΅ΠΉ выТиваСмости – ΠΏΡƒΡ‚Π΅ΠΌ построСния ΠΊΡ€ΠΈΠ²Ρ‹Ρ… доТития ΠΏΠΎ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρƒ Каплана – ΠœΠ΅ΠΉΠ΅Ρ€Π° ΠΈ с использованиСм ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΏΡ€ΠΎΠΏΠΎΡ€Ρ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½Ρ‹Ρ… рисков Кокса. БтатистичСски достовСрными ΡΡ‡ΠΈΡ‚Π°Π»ΠΈΡΡŒ различия ΠΏΡ€ΠΈ Ρ€ < 0,05.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Показано, Ρ‡Ρ‚ΠΎ sPD-1ΠΈ sPD-L1 ΠΎΠ±Π½Π°Ρ€ΡƒΠΆΠΈΠ²Π°ΡŽΡ‚ΡΡ Π² сывороткС ΠΊΡ€ΠΎΠ²ΠΈ ΠΊΠ°ΠΊ Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с онкологичСскими заболСваниями, Ρ‚Π°ΠΊ ΠΈ Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… Π΄ΠΎΠ½ΠΎΡ€ΠΎΠ², ΠΈ ΠΈΡ… ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ Π·Π½Π°Ρ‡ΠΈΠΌΠΎ Π½Π΅ ΠΎΡ‚Π»ΠΈΡ‡Π°ΡŽΡ‚ΡΡ. Показано, Ρ‡Ρ‚ΠΎ высокая концСнтрация sPD-L1 Π² сывороткС ΠΊΡ€ΠΎΠ²ΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½Ρ‹ΠΌ Ρ€Π°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ Π·Π½Π°Ρ‡ΠΈΠΌΠΎ ассоциирована с ΠΏΠΎΠ·Π΄Π½Π΅ΠΉ стадиСй заболСвания ΠΈ являСтся нСзависимым нСблагоприятным прогностичСским Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠΌ. НСобходимо ΠΎΡ‚ΠΌΠ΅Ρ‚ΠΈΡ‚ΡŒ, Ρ‡Ρ‚ΠΎ для ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Ρ€Π°ΠΊΠΎΠΌ ΠΏΠΈΡ‰Π΅Π²ΠΎΠ΄Π° нСблагоприятным прогностичСским ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠΌ являСтся высокоС содСрТаниС растворимой Ρ„ΠΎΡ€ΠΌΡ‹ Ρ€Π΅Ρ†Π΅ΠΏΡ‚ΠΎΡ€Π° PD-1, Π° Π½Π΅ Π΅Π³ΠΎ Π»ΠΈΠ³Π°Π½Π΄Π° PD-L1, ΠΊΠ°ΠΊ для Ρ€Π°ΠΊΠ° Π»Π΅Π³ΠΊΠΎΠ³ΠΎ.Π’Ρ‹Π²ΠΎΠ΄Ρ‹. Π‘ΠΎΠ΄Π΅Ρ€ΠΆΠ°Π½ΠΈΠ΅ Π² сывороткС ΠΊΡ€ΠΎΠ²ΠΈ sPD-1ΠΈ sPD-L1 ΠΌΠΎΠΆΠ΅Ρ‚ ΠΈΠΌΠ΅Ρ‚ΡŒ Ρ€Π°Π·Π»ΠΈΡ‡Π½ΠΎΠ΅ прогностичСскоС Π·Π½Π°Ρ‡Π΅Π½ΠΈΠ΅ для злокачСствСнных ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΠΉ, ΠΈ Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ Π΅Π³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° для клиничСского примСнСния Ρ‚Ρ€Π΅Π±ΡƒΠ΅Ρ‚ дальнСйшСго изучСния

    TECHNOLOGICAL SYSTEM AND A PARISH COMMUNITY

    No full text
    The article considers the issue of how the Orthodox community as the most traditional social community adapts to the contemporary system of technologies. First, the author describes the phenomenon of technological system, identifies its main features, capabilities and limitations. Among the key features of the technological system, the article focuses on decentralization, weakening hierarchy and strengthening horizontal links, flexibility, self-regulation, adaptability, totality and the use of man as an algorithmically acting subject. The author emphasizes that the system approach in sociology plays an important role in the study of technological systems, and N. Luhmann’s approach is relevant for the study of parish communities, though the author mentions the limitations and critique of his works. The article examines contemporary church discourse about modernization of parish communities, which is also determined by the popularization of the views of Luhmann and other representatives of the system approach. The author also focuses on the most important question of the contemporary world under the technological development, which is the future of the mankind, and the article mentions concepts β€˜cyborg’, β€˜mutant’, β€˜clone’, β€˜virtual person’, and β€˜posthuman’. The author makes a number of conclusions about how the parish community will react to the changes of the mankind, and what the most possible risks for the parish communities are considering such changes. Thus, the transformation of the parish community into a well-managed and well-functioning system or network means its rationalization, which at first seems necessary and solving urgent problems, but then one can see that it deprives the community of its vitality: a man finds himself in the community, but it does not seem to be Christian any more

    Value orientations of the student youth in religious and secular universities

    No full text
    The article presents the results of the factor analysis applied to the data of mass survey on the value orientations of the students of secular and religious universities - Moscow Orthodox Theological Academy and Seminary, Lomonosov Moscow State University and Saint Petersburg State University. First, the authors provide a brief overview of the current state of sociological studies of values and value orientations of the youth and Russians with an emphasis on cross-cultural and other comparative contexts, which are so popular today. The article also considers different emphases in the sociological interpretation of the concepts of values and value orientations on the theoretical and empirical levels including the historical perspective. Since the research project consisted of several stages so as to solve a number of tasks and used different formats of the questionnaire for different samples (administration, professors and students), the article presents only a small part of the project designed to reveal the value orientations of students of secular and religious universities with the help of S. Schwartz and B. Bilski technique. The authors used this technique to identify similarities and differences in values and motives of students of secular and religious universities; suggest four factorial types of motivation; offer an interpretation of the observed factors and their manifestations in different student subsamples, such as the different circumstances of life of students in secular and religious universities and the more β€œexpert” status of the latter in the (Christian, Orthodox) moral discourse, unlike the majority of students of secular universities, who can hardly be considered experts in secular ethics

    CHID1 Is a Novel Prognostic Marker of Non-Small Cell Lung Cancer

    No full text
    There is an urgent need for identification of new prognostic markers and therapeutic targets for non-small cell lung cancer (NSCLC). In this study, we evaluated immune cells markers in 100 NSCLC specimens. Immunohistochemical analysis revealed no prognostic value for the markers studied, except CD163 and CD206. At the same time, macrophage markers iNOS and CHID1 were found to be expressed in tumor cells and associated with prognosis. We showed that high iNOS expression is a marker of favorable prognosis for squamous cell lung carcinoma (SCC), and NSCLC in general. Similarly, high CHID1 expression is a marker of good prognosis in adenocarcinoma and in NSCLC in general. Analysis of prognostic significance of a high CHID1/iNOS expression combination showed favorable prognosis with 20 months overall survival of patients from the low CHID1/iNOS expression group. For the first time, we demonstrated that CHID1 can be expressed by NSCLC cells and its high expression is a marker of good prognosis for adenocarcinoma and NSCLC in general. At the same time, high expression of iNOS in tumor cells is a marker of good prognosis in SCC. When used in combination, CHID1 and iNOS show a very good prognostic capacity for NSCLC. We suggest that in the case of lung cancer, tumor-associated macrophages are likely ineffective as a therapeutic target. At the same time, macrophage markers expressed by tumor cells may be considered as targets for anti-tumor therapy or, as in the case of CHID1, as potential anti-tumor agents

    Immunosuppressive peculiarities of stromal cells of various kidney tumor types

    Get PDF
    Background. Renal cell carcinoma is a heterogeneous group of tumors characterized by high vascularization and immunogenicity. Immunotherapy has made a breakthrough in the treatment of this pathology, however, the lack of development of criteria for its use does not allow to achieve even greater success. It is known that the tumor stroma plays an important role in the success of immunotherapy. Among the various histological types of kidney tumors, the stroma of the clear cell renal cell carcinoma has been studied in sufficient detail. However, the remaining histological types are practically not studied.Objective: description of the immunosuppressive phenotype of the stroma of kidney tumors of various histological types.Materials and methods. The study included tumor samples obtainedfrom 44patients with renal cell carcinoma of various histological types (16 samples of chromophobe cancer, 15 samples of clear cell and 13 samples of papillary renal cell carcinoma). The method of immunohis-tochemistry evaluated the expression of tumor stromal markers, namely CD68, CD206, PU.1, CD3, IDO1 and PD-L1 in the studied samples.Results. Analysis of the total number of macrophages associated with the tumor showed that the smallest number is observed in samples of chromophobe renal cancer, while in the samples of clear cell cancer their number is greatest. A similar situation is observed for T-cells: the largest number of CD3+ cells is observed in clear cell tumors. In chromophobe and papillary tumors, their number is reduced. Papillary tumors are also characterized by an almost complete absence of expression of PD-L1 and IDO1 compared to other histological types of kidney tumors. We also showed that for PU.1 there is a strong positive correlation between its quantity and localization, as in CD68. Thus, PU.1 can be used as a general marker for describing stromal macrophages in kidney tumors.Conclusion. The study showed that kidney tumors of various histological types strongly and significantly differ in the composition of their microenvironment. These data, of course, must be considered when choosing immune therapy in the treatment of this pathology

    Gd3+-Doped Magnetic Nanoparticles for Biomedical Applications

    No full text
    Magnetic nanoparticles (MNPs) made of iron oxides with cubic symmetry (Fe3O4, Ξ³-Fe2O3) are demanded objects for multipurpose in biomedical applications as contrast agents for magnetic resonance imaging, magnetically driven carriers for drug delivery, and heaters in hyperthermia cancer treatment. An optimum balance between the right particle size and good magnetic response can be reached by a selection of a synthesis method and by doping with rare earth elements. Here, we present a microwave-assisted polyol synthesis of iron oxide MNPs with actual gadolinium (III) doping from 0.5 to 5.1 mol.%. The resulting MNPs have an average size of 14 nm with narrow size distribution. Their surface was covered by a glycol layer, which prevents aggregation and improves biocompatibility. The magnetic hyperthermia test was performed on 1 and 2 mg/ml aqueous colloidal solutions of MNPs and demonstrated their ability to rise the temperature by 3Β°C during a 20–30 min run. Therefore, the obtained Gd3+ MNPs are the promising material for biomedicine
    corecore